Hemostasis

• 

  Subject Areas on Research

  • "Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis on sepsis-induced coagulopathy in the management of sepsis": reply. 
  • A cell-based model of coagulation and the role of factor VIIa. 
  • A cell-based model of hemostasis. 
  • A cell-based model of thrombin generation. 
  • A model for the tissue factor pathway to thrombin. I. An empirical study. 
  • A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger? 
  • A mouse bleeding model to study oral anticoagulants. 
  • A novel ultrasound-based method to evaluate hemostatic function of whole blood. 
  • A refined model of the genomic basis for phenotypic variation in vertebrate hemostasis. 
  • A review of the therapeutic uses of thrombin. 
  • ABO blood group and bleeding after coronary artery bypass graft surgery. 
  • Actions of thrombin in the interstitium. 
  • Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients. 
  • An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas. 
  • Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. 
  • Anticoagulation management associated with extracorporeal circulation. 
  • Antifibrinolytic therapy: new data and new concepts. 
  • Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. 
  • Association of sleep onset of acute coronary syndrome with sleep apnea syndrome and abnormal diurnal variation of hemostasis and adipokine levels. 
  • Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. 
  • Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists. 
  • Biology of Coagulation and Coagulopathy in Neurologic Surgery. 
  • Bleeding and the new anticoagulants: strategies and concerns. 
  • Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors. 
  • Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. 
  • Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician's view. 
  • Cell-based models of coagulation: a paradigm in evolution. 
  • Cellular interactions in hemostasis. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials. 
  • Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. 
  • Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. 
  • Clinical and laboratory evaluation of the hypercoagulable states. 
  • Coagulation 2006: a modern view of hemostasis. 
  • Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. 
  • Coagulation factor interaction with platelets. 
  • Coagulation in Liver Disease. 
  • Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. 
  • Coagulopathy in COVID-19. 
  • Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. 
  • Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation. 
  • Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. 
  • Comparison of the ultrasonic scalpel to CO2 laser and electrosurgery in terms of tissue injury and adhesion formation in a rabbit model. 
  • Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. 
  • Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor? 
  • Cutaneous wound healing: recruiting developmental pathways for regeneration. 
  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. 
  • Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. 
  • Development and validation of a generalizable model for predicting major transfusion during spine fusion surgery. 
  • Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk. 
  • Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations. 
  • Dose of prophylactic platelet transfusions and prevention of hemorrhage. 
  • Dysregulation of hemostasis by cancer. 
  • Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. 
  • Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. 
  • Effect of streptavidin-biotin on endothelial vasoregulation and leukocyte adhesion. 
  • Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction. 
  • Effects of intracoronary diltiazem on certain hemostatic parameters during acute myocardial infarction in swine. 
  • Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. 
  • Emerging applications of aptamers for anticoagulation and hemostasis. 
  • Emerging paradigms in arterial thrombosis. 
  • Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Factor Xa-A pleuripotential protease. 
  • Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention. 
  • Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. 
  • Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. 
  • First report of the point-of-care TEG: A technical validation study of the TEG-6S system. 
  • Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis. 
  • Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. 
  • Hemostasis and alterations of the central nervous system. 
  • Hemostasis and thrombosis in older adults. 
  • Hemostasis: old system, new players, new directions. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis. 
  • Hemostatic changes after dietary coenzyme Q10 supplementation in swine. 
  • Hemostatic changes after early versus late intracoronary magnesium during acute myocardial infarction in swine. 
  • Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. 
  • Hemostatic effects of therapeutic plasma exchange: A concise review. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. 
  • Highlights from the 46 th annual meeting of the American Society of Hematology. 
  • How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. 
  • Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. 
  • Impaired haemostasis and regional anaesthesia. 
  • Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). 
  • In Response. 
  • In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • Infant cardiopulmonary bypass: a procoagulant state. 
  • Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. 
  • Is there a rationale for antiplatelet therapy in acute heart failure? 
  • Loss of the cytoskeletal protein Pdlim7 predisposes mice to heart defects and hemostatic dysfunction. 
  • Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. 
  • Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine. 
  • Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation. 
  • Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). 
  • Management of gynecologic surgery in the patient with factor XI deficiency: a review of the literature. 
  • Management of hemostasis in vascular surgery. 
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. 
  • Mechanisms and monitoring of bypassing agent therapy. 
  • Mild myocardial stunning affects platelet aggregation and certain hemostatic factors in swine. 
  • Multidisciplinary approach to the challenge of hemostasis. 
  • Nanosilver composite pNIPAm microgels for the development of antimicrobial platelet-like particles. 
  • New techniques for hemostasis during diabetic vitrectomy. 
  • NovoSeven for non-hemophilia hemostasis. 
  • Optimal Hemostatic Band Duration After Transradial Angiography or Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials. 
  • Oxidative Stress and Thrombosis during Aging: The Roles of Oxidative Stress in RBCs in Venous Thrombosis. 
  • Perioperative coagulation management: Evolving strategies. 
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 
  • Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. 
  • Pharmacologic preservation of the hemostatic system during cardiac surgery. 
  • Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. 
  • Platelet binding and activity of recombinant factor VIIa. 
  • Postpartum hemorrhage: when uterotonics and sutures fail. 
  • Practical coagulation for the blood banker. 
  • Predicting and treating coagulopathies after cardiopulmonary bypass in children. 
  • Preoperative Laboratory Studies for Pediatric Cardiac Surgery Patients: A Multi-Institutional Perspective. 
  • Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. 
  • Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR). 
  • Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery. 
  • Pulmonary embolism after administration of recombinant activated Factor VII for major obstetric hemorrhage. 
  • Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. 
  • Radial optic neurotomy in the porcine eye without retinal vein occlusion. 
  • Real-time spectral domain Doppler optical coherence tomography and investigation of human retinal vessel autoregulation. 
  • Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. 
  • Rethinking the coagulation cascade. 
  • Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. 
  • Rotational thromboelastometry-guided transfusion during lumbar pedicle subtraction osteotomy for adult spinal deformity: preliminary findings from a matched cohort study. 
  • Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus. 
  • Scanning electron microscopical observations of two novel hemostatic polymers. 
  • Severe coagulation abnormalities in Reye syndrome. 
  • Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. 
  • Some haematopathological features of marathon running. 
  • Some things I thought I knew about tissue factor that turn out to be wrong. 
  • Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. 
  • Surface-dependent hemostasis. 
  • TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. 
  • Targeting the endothelium in cancer--the importance of the interaction of hemostatic mechanisms and the vascular wall for tumor growth and angiogenesis. 
  • Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy? 
  • Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. 
  • The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. 
  • The Perioperative Management of Ascending Aortic Dissection. 
  • The U.S. Thrombosis and Hemostasis Centers pilot sites program. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The biochemistry of haemostasis. 
  • The cardiopulmonary effects of ambient air pollution and mechanistic pathways: a comparative hierarchical pathway analysis. 
  • The cellular basis of traumatic bleeding. 
  • The central role of thrombin in bleeding disorders. 
  • The clotting system - a major player in wound healing. 
  • The coagulation cascade in cirrhosis. 
  • The convergence of herb pharmacodynamics and herb-drug interactions on hemostasis. 
  • The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The emerging concept of vascular remodeling. 
  • The impact of cigarette smoking on 24-hour blood pressure, inflammatory and hemostatic activity, and cardiovascular risk in Japanese hypertensive patients. 
  • The implementation and efficacy of the Northwestern High Risk Spine Protocol. 
  • The multiple roles of tissue factor in wound healing. 
  • The pathogenesis of vascular thrombosis and its impact in microvascular surgery. 
  • The role of haemophilia treatment centres in providing services to women with bleeding disorders. 
  • The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. 
  • Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. 
  • Thrombophilia and thrombosis in thrombotic thrombocytopenic purpura. 
  • Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. 
  • Thrombotic preparedness in aging: a translatable construct for thrombophilias? 
  • Transfusion and hemostasis in cardiac surgery. 
  • Trauma-induced coagulopathy. 
  • Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. 
  • Update on hemostasis: neurosurgery. 
  • Vascular regulation of plasminogen activator inhibitor-1 activity. 
  • Wound healing in haemophilia--breaking the vicious cycle. 
• 

  Keywords of People

  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Ghadimi, Kamrouz, Associate Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology